This meta-analysis summarizes the available evidence on the testing of new approaches in NAT of TNBC Valrubicin patients and demonstrates the superiority of the testing regimens which integrate novel approaches, in terms of pCR improvement, compared with standard regimens. A wide variability in the range of pCR rate was observed among the studies included in our analysis, mainly due to the Gepartrio study, which included patients who failed to respond after two cycles of NAT resulting in pCR rates of only 12.5% and 4.9% in the control and testing arms. Regarding the use of specific agents, our data supports carboplatin-containing or bevacizumab-containing regimens that achieved statistically higher pCR rates, as was the case with the phase II CALGB 40603 study. Moreover, our meta-analysis included a larger number of TNBC patients allowing to draw more robust conclusions compared to individual phase II studies. Furthermore, we demonstrated that pCR improvement with additional carboplatin or bevacizumab Corylifol A treatment was not associated with a specific controlled chemotherapy regimen, which may reflect its common biological behavior and de novo sensitivity of TNBC to carboplatin or bevacizumab treatment. TNBC is characterized biologically by having a histopathological similarity with germline BRCA1-mutated breast cancer, with 90% of BRCA1-mutation tumors being considered as TNBC. Due to its deficiency of DNA repair mechanisms, BRCA1 mutation-associated TNBC cells are particularly sensitive to DNA-damaging platinum agents, like cisplatin or carboplatin. A phase II study evaluated cisplatin monotherapy as NAT in TNBC patients, showing a pCR rate of 22%. For breast cancer patients with BRCA1 mutation, single-agent cisplatin NAT can achieve an extremely high pCR rate of 83%. Several phase II single-arm studies have tested the combination of taxanes and platinum salts as NAT for TNBC patients, with pCR rates of 33�C77%, indicating that platinum salts are especially active in TNBC treatment. Our findings are consistent with previous phase II studies showing that adding carboplatin to NAT regimens can achieve a pCR rate up to 51.2%. Compared with the nocarboplatin-containing standard NAT regimen, the probability of achieving a pCR was much higher in the carboplatin-containing arm.